Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance
July 30, 2015 7:43 AM EDT
Leerink Partners downgraded Baxter International (NYSE: BAX) from Outperform to Market Perform with a price target of $40.00 (from $82.00).
Analyst Danielle Antalffy commented, "We are downgrading BAX shares to MP with a $40 12-month price target. Despite delivering solid 2Q15 results, post-split new BAX valuation appears lofty to us, already seeming to factor in potential upside in both sales... More
July 29, 2015 4:18 PM EDT
Baxter (NYSE: BAX) declared a quarterly dividend at a new rate of $0.115 per share, or $0.46 annualized, following its successful spin-off of its biopharmaceuticals business, Baxalta Incorporated.
The dividend will be payable on October 1, 2015, to stockholders of record on September 4, 2015, with an ex-dividend... More
July 29, 2015 4:16 PM EDT
Baxter (NYSE: BAX) reported Q2 EPS of $1.00, ex-items, $0.05 better than the analyst estimate of $0.95. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.77 billion.
Baxter sees Q3 2015 EPS of $0.29-$0.31, versus the consensus of $0.27.
''The... More
